sale ep well estim sale ep guidanc rais
ep estim consensu
ep guidanc increas prior rais
ep estim year estim review
sale estim consensu drug
beat estim includ mavyret humira
sale report ex de-stock ou sale help shipment time lupron
androgel sevofluoran creon imbruvica combin
forecast product forecast includ kaletra light synthroid duodopa
combin light kaletra line sale guidanc humira
imbruvica hcv
gpm estim
estim sg forecast net interest
expens estim pre-tax margin
estim tax rate forecast share count
estim
imbruvica ph data cll/sll dlbcl phoenix full data r/r
fl/mzl selen ph ii data pancreat cancer resolv regulatori file dlbcl
wm w/rituxan venclexta ph ii data r/r fl contralto dlbcl caval
initi ph mm mainten r/r fl dlbcl wm w/imbruvica /eu
approv r/r cll w/rituxan file aml upadacitinib ph data
ra select-earli regulatori file initi ph atop dermat gca uc
risankizumab initi ph uc rova-t ph data net basket trial
r/r sclc w/ipi nivo elagolix full ph data uterin fibroid posit top-lin
approv endometriosi pdufa veliparib ph data vela non-sq nsclc
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit hepat
segment oncolog compani pipelin promis agent
opportun upward revis sever front stock attract valu
versu group overal attribut argu purchas share
mavyret nex-gen hcv rollout
elagolix approv endometriosi
humira sale
biosimilar competit
humira biosimilar gain traction
quickli eu and/or launch
especi oncolog
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
cowen compani
chg total good profit margin profit gross gross profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
